Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Seattle Genetics Announces FDA Accelerated Approval of ADCETRIS™ (Brentuximab Vedotin) for Two Indications
Seattle Genetics Announces FDA Accelerated Approval of ADCETRIS™ (Brentuximab Vedotin) for Two Indications
Seattle Genetics Announces FDA Accelerated Approval of ADCETRIS™ (Brentuximab Vedotin) for Two Indications
Submitted by
admin
on August 20, 2011 - 9:56pm
Source:
Yahoo/BusinessWire
News Tags:
systemic anaplastic large cell lymphoma
lymphoma
Hodgkin's lymphoma
Adcetris
Headline:
Seattle Genetics Announces FDA Accelerated Approval of ADCETRIS™ (Brentuximab Vedotin) for Two Indications
Do Not Allow Advertisers to Use My Personal information
